Call Now For a Free Consultation:
(614) 532-4576


Consult with Our Legal Team
You will be contacted by a member of the Investor Claims team within 24 hours.

1 of 13
For The Advocacy You Deserve Contact Us Today!
We’ll respond and let you know the best way to proceed with your case.

Valsartan, Losartan and Irbesartan Claims

Meyer Wilson is pursuing claims related to certain batches of Valsartan, Losartan and Irbesartan which became contaminated with N-nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) but were nevertheless sold to US consumers for years.  

NDMA and NDEA Are Known Human Carcinogens 

NDMA and NDEA are highly potent carcinogenic compounds and have been identified as “cohorts of concern” by world regulatory agencies due to their propensity for causing genetic mutations.  N-Nitroso compounds such as NDMA or NDEA serve no legitimate function aside from being used by researchers to induce cancer in laboratory animals.  

The Nitrosamine Contamination Resulted from the Manufacturers’ Conduct 

As detailed in the master complaint, the Plaintiffs allege that this years-long contamination was a result of systemic and pervasive quality assurance failings occurring at manufacturing facilities in China and India operated by Zhejiang Huahai Pharmaceuticals, Mylan Pharmaceuticals, Teva Pharmaceuticals, Torrent Pharmaceuticals, Aurobindo Pharmaceuticals, and Hetero Labs Limited.   

In 2018, upon discovering that these companies had been manufacturing and selling generic products containing a carcinogen for years, the FDA initiated an unprecedented recall for all unexpired batches of these products. Due to the observed and documented grossly non-compliant quality assurance practices, the FDA also placed many of these companies facilities on import alert, preventing the products manufactured from these facilities from even crossing the border into the United States. 

Meyer Wilson Attorneys Have Been Holding These Manufacturers Accountable 

Layne Hilton, the Lead Counsel in Meyer Wilson’s Mass Torts practice, was appointed to serve on the Plaintiffs’ Steering Committee for the In re Valsartan, Losartan and Irbesartan Products Liability Litigation by the Hon. Robert Kugler of the District of New Jersey. In addition to generally serving on the Discovery, Law and Briefing, and Third-Party Payor committees, Layne was also appointed to serve as the co-chair of the Class Action committee.  Since the beginning of the litigation, Layne has been integrally involved in many aspects of the case, including conducting 30(b)(6) depositions of company witnesses, conducting briefing related to Rule 12(b)(6) and Rule 23 Class Certification, working with experts on developing reports, and arguing discovery issues before the Court.  

The Plaintiffs in the litigation seek recovery for either 1) the economic loss claims for the cost of the drug; 2) the cost of medical monitoring because of taking the drugs, or 3) for personal injuries suffered by those who developed certain cancers because of their ingestion of these defectively manufactured products. 

Meyer Wilson is currently accepting clients who took the contaminated Valsartan, Losartan and Irbesartan and developed the following types of cancer: 

  • Bladder Cancer
  • Blood Cancer
  • Breast Cancer
  • Colorectal/Intestinal Cancer
  • Esophageal Cancer 
  • Gastric Cancer
  • Kidney Cancer 
  • Liver Cancer
  • Lung Cancer
  • Pancreatic Cancer 
  • Prostate Cancer
  • Uterine Cancer 

If you would like to speak to someone about a potential claim related to your purchase and/or consumption of these products, please contact Meyer Wilson at (614) 532-4576

Meyer Wilson
Meyer Wilson
Quick Links
The information contained in this Website is provided for informational purposes only, and should not be construed as legal advice on any subject matter. No recipients of content from this site, clients or otherwise, should act or refrain from acting on the basis of any content included in the site without seeking the appropriate legal or other professional advice on the particular facts and circumstances at issue from an attorney licensed in the recipient's state. Read More
The information contained in this Website is provided for informational purposes only, and should not be construed as legal advice on any subject matter. Read More
crosschevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram